Clinical trials: MIS-C Multisystem Inflammatory Syndrome in Children
Multisystem Inflammatory Syndrome in Children (MIS-C), SARS-CoV-2 Infection
Cardiovascular Assessment 5 Years After MIS-C
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication associated with SARS-CoV-2 infection that frequently affects the cardiovascular system.
- Trial name
- NCT07659847
- Where
- Poland
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Multisystem Inflammatory Syndrome in Children (MIS-C)
Quality of Life in Children After Multisystem Inflammatory Syndrome in Children
The aim of this observational study is to assess whether Multisystem Inflammatory Syndrome (MIS-C) in children affects their quality of life.
- Trial name
- MIS-C (NCT07126028)
- Where
- Croatia
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Kristina Lah Tomulić
Myocarditis
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
The purpose of this study is to learn about the safety and effects of the vaccine (called COMIRNATY) for the potential prevention of COVID-19. This study is seeking participants who: 1. Are age <21 years. 2.
- Trial name
- NCT05295290
- Testing
- Cardiac Imaging
- Where
- 18 sites in United States
- Volunteers
- 319 people
- Sponsor
- Pfizer
Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
Contrast Enhanced Ultrasound in COVID-19
Initial data from COVID-19 patients suggests that one of the primary causes of death is significant endothelial injury leading to blood clotting and impaired multiorgan microvascular perfusion.
- Trial name
- NCT04640038
- Testing
- Sulfur hexafluoride lipid-type A microspheres
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Children's Hospital of Philadelphia
Multisystem Inflammatory Syndrome in Children, COVID-19
COVID-19: Immunological Mechanisms in Multisystem Inflammatory Syndrome in Children
This study seeks to explore immunological mechanisms in patients with Multisystem Inflammatory Syndrome in Children (MIS-C) to improve the understanding of this pathogenesis of this disease.
- Conditions
- Multisystem Inflammatory Syndrome in Children, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT05334134
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Covid19; MIS-C
Coronavirus-19 (COVID-19) and Related Outcomes in School Aged Children (ABC Health Outcomes in Children)
This is a prospective, observational study with a primary objective of determining the incidence of non-severe and severe COVID-19, including MIS-C, among eligible children who are diagnosed with COVID-19 and consent (or assent)…
- Trial name
- NCT04757831
- Volunteers
- healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, MIS-C Associated With COVID-19
Exercise Fatigue Parameters and Endothelial Function in Pediatric Patients With a History of COVID-19 Infection or MIS-C
Acute coronavirus disease 2019 (COVID-19) infection can include cardiac and pulmonary manifestations as well as post-infectious complications such as multisystem inflammatory syndrome (MIS-C), also known as pediatric inflammatory…
- Trial name
- NCT05205642
- Testing
- Cardiopulmonary exercise test (CPET), Peripheral Arterial Tonography (PAT) using the EndoPAT™ device, Endothelin
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Rambam Health Care Campus
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C)
COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
The primary objectives of this study are: To determine the proportion of children with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) related death, rehospitalization or major complications after infection with…
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
- Trial name
- PRISM (NCT04588363)
- Testing
- SARS-CoV-2 and/or MIS-C Exposure
- Where
- 20 sites in United States
- Volunteers
- 244 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multisystem Inflammatory Syndrome-Children
MIS-C Comparative Effectiveness Study
In March 2020, children exposed to the virus that causes the COVID-19 illness, SARS-CoV-2, presented with fever and significant inflammation about a month after exposure to the virus.
- Trial name
- MISTIC (NCT04898231)
- Testing
- Infliximab, Anakinra, Methylprednisolone
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- University of California, San Diego
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.
- Trial name
- NCT04456439
- Testing
- Remestemcel-L, Hydrocortisone, Diphenhydramine
- Sponsor
- Mesoblast International Sàrl